New analyses on baricitinib presented at EULAR

16 June 2017

Eli Lilly (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) have announced new data from eight Olumiant (baricitinib) clinical trials at EULAR, the Annual European Congress of Rheumatology, in Madrid.

The data show similar rates of serious infection incidents in patients with moderate-to-severe rheumatoid arthritis treated with Olumiant and those treated with a placebo.

In terms of efficacy, the companies presented more positive news. One analysis showed that at two years, progression of structural joint damage, by a commonly-used measure, was significantly lower in patients treated with the drug.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK